DURHAM, N.C. --(BUSINESS WIRE)--Sep. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
- Roclanda ® Achieves Non-Inferiority to Ganfort ® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 8, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
